OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2021-12-29 02:42:21

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Equine influenza
Address of laboratory:	Equine Research Institute Japan Racing Association 1400-4 Shiba Shimotsuke Tochigi 329-0412 JAPAN
Tel.:	+81-285 44.0090
Fax:	
E-mail address:	manabu_nemoto@jra.go.jp
Website:	http://japanracing.jp/en/about/jra_organization/jeri.html
Name (including Title) of Head of Laboratory (Responsible Official):	Shinya Wada DVM, PhD, Director
Name (including Title and Position) of OIE Reference Expert:	Manabu Nemoto DVM, PhD
Which of the following defines your laboratory? Check all that apply:	Other: Horse racing authority

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
Haemagglutination Inhibition	Yes	12	0
Direct diagnostic tests		Nationally	Internationally
Conventional RT-PCR	No	811	0

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
H3N8 Equine influenza virus RNA	RT-PCR	Produced	0.6ml	0	1	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
UNITED STATES OF AMERICA	Protocol of neutralisation test	E-mail

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Antigenic characterisation of Florida sublineage clade 1 strains isolated in 2019 in Europe	2019-2021	To evaluate the effectiveness of these vaccines against Florida sublineage clade strains detected in Europe in 2019.	Irish Equine Centre	IRELAND

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
- We performed RT-PCR for equine influenza using nasal swabs collected from febrile racehorses in Japan, and they were all negative. - We performed the antigenic characterisation of recently circulating strains to evaluate the vaccine efficacy.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
We submitted the data to the OIE expert surveillance panel on equine influenza vaccine composition. The data of antigenic analysis has been published in a peer-reviewed journal listed below.

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 1
1. Nemoto M, Ohta M, Yamanaka T, Kambayashi Y, Bannai H, Tsujimura K, Yamayoshi S, Kawaoka Y, Cullinane A. 2021. Antigenic differences between equine influenza virus vaccine strains and Florida sublineage clade 1 strains isolated in Europe in 2019. Vet J 272:105674.

b) International conferences: 1
Ohta M, Bannai H, Kambayashi Y, Tsujimura K, Iwamoto Y, Wakuno A, Yamayoshi S, Kawaoka Y, Nemoto M. September 27th-October 1st, 2021. Antibody responses to a reverse genetics-derived bivalent inactivated equine influenza vaccine in Thoroughbred horses. 11th International Equine Infectious Disease Conference, Virtual meeting

c) National conferences: 0

d) Other:
(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO17025	ISO17025 L20-433.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Haemagglutination Inhibition	Perry Johnson Laboratory Accreditation (PJLA)
Conventional RT-PCR	Perry Johnson Laboratory Accreditation (PJLA)

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
OIE expert surveillance panel on equine influenza vaccine composition	July 2021	Videoconference	Speaker	Cross-virus neutralisation test of horse antisera against Florida sublineage clade 1 strains

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the

same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
OIE expert surveillance panel on equine influenza vaccine composition	Evaluation of vaccine efficacy against recently circulating strains	- Irish Equine Centre - Gluck Equine Research Center, University of Kentucky

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report: